Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.62 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752612 | 0.88 | NOTUM (0.76) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL29808797 | 0.88 | NOTUM (0.76) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL4157201 | 0.87 | CYP1A2 (0.52) | NOTUMBRD9ELANECYP1A2MAPT | |
| SCHEMBL4157208 | 0.87 | NOTUM (0.56) | NOTUMPOLBELANEFAAHCYP1A2 | |
| SCHEMBL8065166 | 0.85 | NOTUM (0.65) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL4147646 | 0.85 | NOTUM (0.54) | NOTUMPOLBELANEFAAHCYP1A2 | |
| SCHEMBL984085 | 0.84 | NOTUM (0.64) | NOTUMBRD9POLBELANECYP1A2 | |
| SCHEMBL5789094 | 0.83 | NOTUM (0.62) | NOTUMPOLBELANEFAAHCYP1A2 | |
| SCHEMBL560810 | 0.82 | NOTUM (0.61) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL8063220 | 0.82 | NOTUM (0.61) | NOTUMPOLBELANECYP1A2ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | disclosed |
| CN-101142189-A | 2-pyridine derivatives as inhibitors of neutrophile elastase | ASTRAZENECA AB (SE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | NOTUM 2923/4885BRD9 3410/4885POLB 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.